Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1388562 | 1.00 | DHFR (1.00) | DHFRADORA1ADORA2APTPN11TDO2 | |
| SCHEMBL30401146 | 0.83 | DHFR (0.71) | DHFRADORA1ADORA2AMAP4K4FGFR1 | |
| SCHEMBL1388358 | 0.83 | DHFR (0.71) | DHFRADORA1ADORA2AMAP4K4FGFR1 | |
| SCHEMBL1388590 | 0.82 | DHFR (0.70) | DHFRADORA1ADORA2AMAP4K4FGFR1 | |
| SCHEMBL27631899 | 0.81 | DHFR (0.69) | DHFRADORA1ADORA2A | |
| SCHEMBL30488016 | 0.80 | ADORA1 (0.70) | DHFRADORA1ADORA2AMAP4K4FGFR1 | |
| SCHEMBL1388335 | 0.80 | DHFR (0.67) | DHFRADORA1ADORA2AFGFR1 | |
| SCHEMBL1388331 | 0.80 | DHFR (0.67) | DHFRADORA1ADORA2AMAP4K4 | |
| SCHEMBL1388276 | 0.80 | ADORA1 (0.70) | DHFRADORA1ADORA2AMAP4K4FGFR1 | |
| SCHEMBL1116404 | 0.80 | ADORA1 (0.70) | DHFRADORA1ADORA2AMAP4K4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | KEAP1, GSTK1, NFE2L2 | DHFR 1701/4885ADORA1 3948/4885ADORA2A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.